PLoS ONE (Jan 2018)

Saccharomyces cerevisiae as a platform for assessing sphingolipid lipid kinase inhibitors.

  • Yugesh Kharel,
  • Sayeh Agah,
  • Tao Huang,
  • Anna J Mendelson,
  • Oluwafunmilayo T Eletu,
  • Peter Barkey-Bircann,
  • James Gesualdi,
  • Jeffrey S Smith,
  • Webster L Santos,
  • Kevin R Lynch

DOI
https://doi.org/10.1371/journal.pone.0192179
Journal volume & issue
Vol. 13, no. 4
p. e0192179

Abstract

Read online

Successful medicinal chemistry campaigns to discover and optimize sphingosine kinase inhibitors require a robust assay for screening chemical libraries and for determining rank order potencies. Existing assays for these enzymes are laborious, expensive and/or low throughput. The toxicity of excessive levels of phosphorylated sphingoid bases for the budding yeast, Saccharomyces cerevisiae, affords an assay wherein inhibitors added to the culture media rescue growth in a dose-dependent fashion. Herein, we describe our adaptation of a simple, inexpensive, and high throughput assay for assessing inhibitors of sphingosine kinase types 1 and 2 as well as ceramide kinase and for testing enzymatic activity of sphingosine kinase type 2 mutants. The assay was validated using recombinant enzymes and generally agrees with the rank order of potencies of existing inhibitors.